Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11184672 | 0.85 | CCR5 (0.56) | TDP1CCR5PTGESALDH1A1LMNA | |
| SCHEMBL5190090 | 0.84 | TDP1 (0.71) | TDP1CCR5PTGESALDH1A1LMNA | |
| SCHEMBL3621820 | 0.82 | TDP1 (0.50) | TDP1CCR5PTGESALDH1A1LMNA | |
| SCHEMBL1850325 | 0.81 | APOBEC3G (0.50) | TDP1CCR5PTGESALDH1A1LMNA | |
| SCHEMBL17479365 | 0.81 | GBA1 (0.44) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4663012 | 0.81 | TDP1 (0.62) | TDP1CCR5PTGESMAPT | |
| SCHEMBL411205 | 0.81 | AOC3 (0.53) | TDP1CCR5ALDH1A1LMNA | |
| SCHEMBL8356647 | 0.81 | TDP1 (0.62) | TDP1CCR5PTGESMAPT | |
| SCHEMBL9289307 | 0.79 | TDP1 (0.59) | TDP1CCR5PTGESALDH1A1LMNA | |
| SCHEMBL16222119 | 0.79 | CCR5 (0.51) | TDP1CCR5PTGESALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649618-B2 | Prevention and/or therapy of ischaemia and reperfusion damage; poly(ADP-ribose)-synthetase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| EP-1303497-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002006247-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | TDP1 74/4885CCR5 4558/4885HTR7 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.